PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era.

"Conflicts of interest M.J.C. reports the following disclosures: honoraria/grants for advisory boards/speaker/research funding from Amgen, Astrazeneca, CSL, Kowa, MSD, Pfizer, Sanofi-Regeneron, and Unilever. H.N.G. reports the following disclosures: honoraria/grants for advisory boards/speaker/research funding from Sanofi-Regeneron, Amgen, Merck, Kowa, Lilly, Resverlogix, and Bristol-Myers-Squibb. J.K.S. has no conflicts of interest. All authors contributed equally to the conception and realization of this manuscript. J.K.S. performed the literature search for the period 2013–2015."

"Financial support and sponsorship PCSK9 Forum is a not-for-profit organization established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. The Forum is registered in the UK, and receives unrestricted educational grants from the healthcare industry."